Home | Welcome to Contract Pharma   
Last Updated Friday, July 25 2014
Print

Financial Report: Merck 3Q



Published October 26, 2012
Merck

3Q Revenues: $11.5 billion (-4%)
 
3Q Earnings: $1.8 billion (+2%)
 
YTD Revenues: $35.5 billion (-1%)
 
YTD Earnings: $5.4 billion (+10%)
 
Comments: Pharmaceutical sales were down 5% to $9.9 billion, including a 5% negative impact from foreign exchange and the loss of market exclusivity for Singulair in the U.S. in August (-55% to $602 million). Januvia sales were up 15% to $975 million. Zetia sales were up 5% to $645 million. Gardasil sales were up 31% to $581 million. Janumet and Isentress sales were up 16% to $405 and $399 million, respectively. Combined sales of Remicade and Simponi declined 9% to $576 million in the quarter. Animal Health sales were down 1% to $815 million. Consumer Care revenues were up 7% to $451 million.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On